-
EP3697431
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3697431
| EP3697431 - TREATMENT OF NEUROPATHY WITH DNA CONSTRUCT EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTINOIDS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 03.05.2024 Database last updated on 13.11.2024 | |
| Former | Request for examination was made Status updated on 24.07.2020 | ||
| Former | The international publication has been made Status updated on 26.04.2019 | Most recent event Tooltip | 03.05.2024 | Withdrawal of application | published on 05.06.2024 [2024/23] | Applicant(s) | For all designated states Helixmith Co., Ltd 21, Magokjungang 8-ro 7-gil Gangseo-gu Seoul 07794 / KR | [2020/35] | Inventor(s) | 01 /
KIM, Sun Young ViroMed Co. Ltd. Building 203 Seoul National University 1 Gwanak-ro, Gwanak-gu Seoul 08826 / KR | 02 /
LEE, Jung Hun ViroMed Co. Ltd. Building 203 Seoul National University 1 Gwanak-ro, Gwanak-gu Seoul 08826 / KR | [2020/35] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2020/35] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 18868758.6 | 16.10.2018 | [2020/35] | WO2018KR12196 | Priority number, date | US201762574100P | 18.10.2017 Original published format: US 201762574100 P | [2020/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019078586 | Date: | 25.04.2019 | Language: | EN | [2019/17] | Type: | A1 Application with search report | No.: | EP3697431 | Date: | 26.08.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application. | [2020/35] | Search report(s) | International search report - published on: | AT | 25.04.2019 | (Supplementary) European search report - dispatched on: | EP | 06.08.2021 | Classification | IPC: | A61K38/18, A61K48/00, A61K31/711, C07K14/475 | [2020/35] | CPC: |
A61P25/02 (EP,KR,US);
A61K48/005 (KR);
A61K48/0016 (US);
A61K38/1833 (KR);
A61K48/0075 (KR,US);
A61K48/0083 (KR,US);
A61K48/0091 (US);
A61P25/04 (EP,KR,US);
A61P29/02 (EP,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/35] | Title | German: | BEHANDLUNG VON NEUROPATHIEN MIT EINEM HGF-ISOFORMEN EXPRIMIERENDEN DNA-KONSTRUKT MIT REDUZIERTER INTERFERENZ VON GABAPENTIINOIDEN | [2020/35] | English: | TREATMENT OF NEUROPATHY WITH DNA CONSTRUCT EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTINOIDS | [2020/35] | French: | TRAITEMENT DE NEUROPATHIE AVEC UNE CONSTRUCTION D'ADN EXPRIMANT DES ISOFORMES DE HGF AVEC UNE INTERFÉRENCE RÉDUITE À PARTIR DE GABAPENTINOÏDES | [2020/35] | Entry into regional phase | 15.05.2020 | National basic fee paid | 15.05.2020 | Search fee paid | 15.05.2020 | Designation fee(s) paid | 15.05.2020 | Examination fee paid | Examination procedure | 15.05.2020 | Examination requested [2020/35] | 02.03.2022 | Amendment by applicant (claims and/or description) | 26.04.2024 | Application withdrawn by applicant [2024/23] | Fees paid | Renewal fee | 14.10.2020 | Renewal fee patent year 03 | 29.09.2021 | Renewal fee patent year 04 | 15.09.2022 | Renewal fee patent year 05 | 27.09.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO9936103 (UNIV MCGILL [CA], et al) [I] 7,8* page 5, line 15 - line 20 *; | [IY]US2014296142 (KIM JONG MOOK [KR], et al) [I] 7,10,11 * claims 19-21 * * paragraph [0001] * * paragraph [0129] * * example 4 * [Y] 1; | [E]WO2019221528 (HELIXMITH CO LTD [KR]) [E] 1,10,11 * claims 1,15,22-24 * * paragraph [0113] * * paragraph [0089] * * paragraph [0125]; paragraph [0127] *; | [E]WO2020079489 (HELIXMITH CO LTD [KR]) [E] 1,7,8,10,11 * paragraph [0003] * * paragraph [0200] - paragraph [0201] * * paragraph [0193] * * paragraphs [0225], [0228], [0230] *; | [XDYI] - JOHN A. KESSLER ET AL, "Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy", ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, GB, (20150305), vol. 2, no. 5, doi:10.1002/acn3.186, ISSN 2328-9503, pages 465 - 478, XP055597022 [XD] 12 * abstract * * page 470, column left * * page 467, column right, paragraph 1 - paragraph 2 * * tables 1, 2 * [Y] 1 [I] 7,9-11 DOI: http://dx.doi.org/10.1002/acn3.186 | International search | [Y]WO9936103 (UNIV MCGILL [CA], et al) [Y] 8 * page 6, lines 15-19; claims 1-5 *; | [Y]JP2006045204 (ANGES MG INC) [Y] 8 * [online translation © TXPJPEA / 2017 Clarivate Analytics, derived from EPOQUE on 15.02.2019] - paragraphs [0003]-[0005]; claims 1, 2, 8, 17, 18 *; | [XY]US2014296142 (KIM JONG MOOK [KR], et al) [X] 1-7, 10-12 * paragraphs [0007] [0015] [0049] [0098]-[0108][0154]-[0193] paragraph [0006] * [Y] 8; | [XY] - KESSLER, J.A. et al., "Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy", Annals of clinical and translational neurology, (20150501), vol. 2, no. 5, pages 465 - 478, XP055597022 [X] 1-7, 10-12 * the whole document abstract * [Y] 8 DOI: http://dx.doi.org/10.1002/acn3.186 | [A] - "PREGABALIN: NEW DRUG. VERY SIMILAR TO GABAPENTIN", PRESCRIRE INT., vol. 14, no. 80, (20051200), page 2036, (20190215), XP055697165 [A] 1-8, 10-12 * () Medline abstract NLM 1 6397976 * |